BACKGROUND: Niban was initially identified in the Eker rat, a model of renal carcinogenesis. We examined Niban expression in head and neck squamous cell carcinoma (HNSCC) and head and neck dysplastic lesions. METHODS: Using a polyclonal rabbit anti-human Niban antibody, 43 cases of HNSCC and 30 cases of head and neck squamous dysplasia were immuonohistochemically stained for Niban. Ancillary genetic studies were also performed. RESULTS: Forty-two of 43 HNSCCs (97.6%) and 20 of 30 (66.6%) dysplastic lesions were positively stained for Niban. The staining was generally less intense in cases of dysplasia than HNSCC. Three of 8 normal mucosal samples from drinker/smokers also showed weak Niban expression. Normal head and neck squamous epithelium from nondrinker/nonsmokers did not stained for Niban. Reverse transcription polymerase chain reaction results matched the immuonohistochemical results. CONCLUSION: The expression of Niban frequently begins in the early stages of head and neck squamous carcinoma and remains upregulated throughout the carcinogenic process. Niban may be a good molecular marker of HNSCC.
BACKGROUND:Niban was initially identified in the Eker rat, a model of renal carcinogenesis. We examined Niban expression in head and neck squamous cell carcinoma (HNSCC) and head and neck dysplastic lesions. METHODS: Using a polyclonal rabbit anti-humanNiban antibody, 43 cases of HNSCC and 30 cases of head and neck squamous dysplasia were immuonohistochemically stained for Niban. Ancillary genetic studies were also performed. RESULTS: Forty-two of 43 HNSCCs (97.6%) and 20 of 30 (66.6%) dysplastic lesions were positively stained for Niban. The staining was generally less intense in cases of dysplasia than HNSCC. Three of 8 normal mucosal samples from drinker/smokers also showed weak Niban expression. Normal head and neck squamous epithelium from nondrinker/nonsmokers did not stained for Niban. Reverse transcription polymerase chain reaction results matched the immuonohistochemical results. CONCLUSION: The expression of Niban frequently begins in the early stages of head and neck squamous carcinoma and remains upregulated throughout the carcinogenic process. Niban may be a good molecular marker of HNSCC.
Authors: Sophia Doll; Anatoly Urisman; Juan A Oses-Prieto; David Arnott; Alma L Burlingame Journal: Mol Cell Proteomics Date: 2016-11-10 Impact factor: 5.911
Authors: Juan Carlos Higareda-Almaraz; Juan S Ruiz-Moreno; Jana Klimentova; Daniela Barbieri; Raquel Salvador-Gallego; Regina Ly; Ilse A Valtierra-Gutierrez; Christiane Dinsart; Gabriel A Rabinovich; Jiri Stulik; Frank Rösl; Bladimiro Rincon-Orozco Journal: BMC Cancer Date: 2016-08-24 Impact factor: 4.430
Authors: Alexandra G Evstafieva; Irina E Kovaleva; Maria S Shoshinova; Andrei V Budanov; Peter M Chumakov Journal: PLoS One Date: 2018-02-08 Impact factor: 3.240
Authors: Luka Brčić; Ana Barić; Benjamin Benzon; Marko Brekalo; Sanda Gračan; Dean Kaličanin; Veselin Škrabić; Tatijana Zemunik; Maja Barbalić; Ivana Novak; Valdi Pešutić Pisac; Ante Punda; Vesna Boraska Perica Journal: Sci Rep Date: 2020-02-04 Impact factor: 4.379